Sigrun Ådnegard Skarstad

Sigrun Ådnegard Skarstad

Auto-generated profile, based on publicly available information

Sigrun Ådnegard Skarstad

ProCardio Center for Innovation, Department of Cardiology Oslo University Hospital, Rikshospitalet Oslo Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2025 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Closed access
HGHalvard Grendstad
Halvard Grendstad
SSSigrun Ådnegard Skarstad
Sigrun Ådnegard Skarstad
TEThor Edvardsen
Thor Edvardsen
JHJostein Hallén
Jostein Hallén

8 December 2021 in Cardiology
Verified
Journal Article
Closed access
PDF file
PMPer Morten Mølstad
Per Morten Mølstad
JNJan Erik Nordrehaug
Jan Erik Nordrehaug
TSTerje K. Steigen
Terje K. Steigen
TWTom Wilsgaard
Tom Wilsgaard
RWRune Wiseth
Rune Wiseth
KBKaare Harald Bønaa
Kaare Harald Bønaa
Background: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary intervention in native vessels and SVG. Aims: The aim of this study was to compare the rate of mortality, MI, and TLR across stent and vessel types. Methods: In this substudy, 6,087 patients with a single lesion in native vessels and 164 in SVG were followed for 5 years. Results: MI was more frequent in SVG (subdistributional hazard ratio [SHR] 4.95 (3.75–6.54, p < 0.001), but not affected by stent type. In the first 500 days, DES reduced TLR in native vessels (SHR 0.21 (0.15–0.30) p < 0.001) and SVG (SHR 0.18 (0.04–0.80) p = 0.02). Thereafter, DES and BMS were equivalent in native vessels, but DES had a higher TLR rate than BMS in SVG (SHR 3.31 (1.23–8.94) p = 0.02). After 5 years, the TLR rate was still significantly lower for DES in native vessels (3.2% vs. 7.8%, p < 0.001) but not in SVG (21.4% vs. 18. 4%). Conclusion: In SVG, no difference in TLR between DES and BMS was observed after 5 years in contrast to persistent benefit in native vessels. The high rate of TLR and MI in SVG makes treatment of native vessels a preference whenever feasible and better treatment options for SVG are warranted.